Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ARGXBullishM&Anews

High materiality9/10

Argenx Completes Forte Acquisition, Adds FB102 to Immunology Pipeline

Aug 27, 2026, 8:53 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Cash-based acquisition with clear value to Forte holders reduces sale risk and signals strategic pipeline expansion. Historic analogs show stock re-rating when large biotech asset acquisitions close with minimal dilution and visible near-term data catalysts (e.g., readouts driving upside).

AI summary

What happened, with direct paths to the underlying reporting

ARGX announced the completed Forte acquisition, adding FB102, a first-in-class anti-CD122 antibody, to its immunology portfolio. FB102 has proof-of-concept in vitiligo and celiac disease, with Phase 2 celiac data due in 2H2026 and vitiligo readouts in 2026. The cash deal expands the pipeline and broadens ARGX's autoimmune indications.

argenx completes Forte acquisition; adds FB102 anti-CD122 antibody.
FB102 targets pathogenic T- and NK-cells; celiac data due 2H2026.
Offer price $77 per Forte share; 87.13% tendered.
Forte becomes ARGX subsidiary and will be delisted.
FB102 expands ARGX's immunology pipeline toward autoimmune indications.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Argenx Completes Forte Acquisition, Adds FB102 to Immunology Pipeline

argenx Announces Positive Phase 3 ALKIVIA Topline for VYVGART Hytrulo in Autoimmune Myositis

Argenx to acquire Forte Biosciences for $2.2B, expanding CD122 pipeline

Argenx Reframes Phase 3 Myositis Readout; IMNM Upside Supports Bullish View

ARGX Gains on FDA Expansion of VYVGART Usage in Myasthenia Gravis